

Primary Care Practice referrals to Monoclonal Antibody Infusions

- Monoclonal antibodies (mAbs) directly neutralize the COVID-19 virus and are intended to prevent the progression of disease
- mAbs are likely to be most beneficial if given to patients early in symptom progression
- Product delivered via single IV infusion administration
- Early evidence suggest promise of mAb products in **outpatient** settings to **reduce hospitalization**

Process to refer your patients

1. Review patient eligibility criteria

for patients with mild-moderate symptoms. Full criteria listed by FDA (Bamlanivimab, Casirivimab and Imdevimab).

2. Perform a COVID-19 PCR or Point-of-Care Rapid Antigen Test

(POC Antigen Tests can be supplied by MDH: complete this form if interested).

3. Refer your positive patients to a partnering infusion site* ASAP

to start treatment within 10 days of onset of symptoms.

Option 1

Send an e-Referral via the CRISP Unified Landing Page (Starter guide: pp. 1-7, 24-34)

OR

Option 2

Complete this referral form and submit directly to infusion site

Adult Eligibility Criteria

At least 1 of the following:

1. BMI ≥ 35 ;
2. Chronic kidney disease;
3. Diabetes;
4. Immunosuppressive disease;
5. Receiving immunosuppressive treatment;
6. Age ≥ 65 years; OR
7. Age ≥ 55 years AND have any of the following:
 - Cardiovascular disease
 - Hypertension
 - COPD/other chronic respiratory disease

***As of 1/19/21, sites are as follows (in alphabetical order):** Adventist – Takoma Park, Atlantic General, Baltimore Convention Center Field Hospital, MedStar Southern Maryland, Meritus Health, Peninsula Regional-Tidal Health, UMPC